Costantini Lauren C, Barr Linda J, Vogel Janet L, Henderson Samuel T
Accera Inc., Interlocken Crescent, Broomfield, CO 80021, USA.
BMC Neurosci. 2008 Dec 3;9 Suppl 2(Suppl 2):S16. doi: 10.1186/1471-2202-9-S2-S16.
The pathology of Alzheimer's disease (AD) is characterized by cerebral atrophy in frontal, temporal, and parietal regions, with senile plaques, dystrophic neurites, and neurofibrillar tangles within defined areas of the brain. Another characteristic of AD is regional hypometabolism in the brain. This decline in cerebral glucose metabolism occurs before pathology and symptoms manifest, continues as symptoms progress, and is more severe than that of normal aging. Ketone bodies are an efficient alternative fuel for cells that are unable to metabolize glucose or are 'starved' of glucose. AC-1202 is designed to elevate serum ketone levels safely. We previously showed that treatment with AC-1202 in patients with mild-to-moderate AD improves memory and cognition. Treatment outcomes were influenced by apolipoprotein E genotype status. These data suggest that AC-1202 may be an effective treatment for cognitive dysfunction by providing an alternative substrate for use by glucose-compromised neurons.
阿尔茨海默病（AD）的病理学特征为额叶、颞叶和顶叶区域的脑萎缩，脑内特定区域出现老年斑、营养不良性神经突和神经原纤维缠结。AD的另一个特征是脑内区域性代谢减退。这种脑葡萄糖代谢下降在病理和症状出现之前就已发生，随着症状进展持续存在，且比正常衰老更为严重。酮体是无法代谢葡萄糖或“缺乏”葡萄糖的细胞的一种有效替代燃料。AC - 1202旨在安全地提高血清酮水平。我们之前表明，在轻度至中度AD患者中使用AC - 1202治疗可改善记忆和认知。治疗结果受载脂蛋白E基因型状态影响。这些数据表明，AC - 1202可能通过为葡萄糖受损的神经元提供替代底物，成为治疗认知功能障碍的有效方法。
